Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 tolerability study of NPC-33 and NPC-26sc in high-risk refractory or incompletely responsive neuroblastoma
jRCT2031240693Phase 1Active, not recruiting
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of naxitamab and sargramostim in neuroblastoma, sponsored by Nobelpharma Co., Ltd. Primary endpoint: All treatment-emergent adverse events (TEAEs) occurring before the end of Cycle 1. Started Apr 2025; status: active, not recruiting.
02
Drugs
naxitamabsargramostim
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on jRCT2031240693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240693.